2/12/2021: Disclosing Amyloid Biomarker Results in Preclinical Alzheimer's Disease

2/12/2021: Disclosing Amyloid Biomarker Results in Preclinical Alzheimer's DiseaseПодробнее

Phase III AHEAD 3-45 trial of lecanemab for preclinical Alzheimer’s diseaseПодробнее

Looking Toward the Future: How Preclinical Alzheimer’s Disease Biomarker Disclosures Impact SocietyПодробнее

The Case for Disclosing Biomarker Results to Alzheimer’s Research ParticipantsПодробнее

Deconstructing Alzheimer’s Disease Complexity to Identify Resilience MechanismsПодробнее

Beyond amyloid & tau: neuroinflammation, rhes & proteomicsПодробнее

Under the Hood: Tracking Preclinical Alzheimer's Disease with BiomarkersПодробнее

Blood-based biomarkers as surrogates of amyloid burden in preclinical Alzheimer's diseaseПодробнее

Safely Disclosing Amyloid Results with Alzheimer’s Disease Research ParticipantsПодробнее

Biomarkers for Alzheimer’s disease in a preclinical settingПодробнее

Biomarkers for early detection of Alzheimer’s disease: microRNAsПодробнее

Second generation of anti-amyloid monoclonal antibodies for Alzheimer's diseaseПодробнее

ADNI: developing biomarkers for Alzheimer’s diseaseПодробнее

Blood-based biomarkers for treatment monitoring in Alzheimer’s diseaseПодробнее

Discover Dementia BiomarkersПодробнее

Plenary 2: From Biomarkers to Precision Medicine in Alzheimer's DiseaseПодробнее

Prognostic blood biomarkers in the pre-clinical stages of Alzheimer’s diseaseПодробнее

Biomarkers for Alzheimer’s disease: past, present and futureПодробнее

sGFAP: a potential diagnostic and prognostic marker in FTDПодробнее

Alzheimer Europe 2020 Conference, Representing dementia pathology w. autogenerated Biomarker ReportsПодробнее